These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 21707532)
1. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532 [TBL] [Abstract][Full Text] [Related]
2. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. Fiorucci S; Di Giorgio C; Distrutti E Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552 [TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor: from medicinal chemistry to clinical applications. Fiorucci S; Mencarelli A; Distrutti E; Zampella A Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613 [TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Ho PP; Steinman L Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264 [TBL] [Abstract][Full Text] [Related]
6. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Cipriani S; Mencarelli A; Palladino G; Fiorucci S J Lipid Res; 2010 Apr; 51(4):771-84. PubMed ID: 19783811 [TBL] [Abstract][Full Text] [Related]
7. Targeting farnesoid X receptor for liver and metabolic disorders. Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816 [TBL] [Abstract][Full Text] [Related]
8. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173 [TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal FXR Ligands: Current Status and Clinical Applications. Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of farnesoid X receptor agonists. Ali AH; Carey EJ; Lindor KD Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637 [TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid-a new therapy in PBC and NASH. Chapman RW; Lynch KD Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030 [TBL] [Abstract][Full Text] [Related]